Johnson & Johnson (N:JNJ)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 1 Johnson And Johnson Plz
Tel: N/A
IR: See website
Key People
Alex Gorsky
Chairman of the Board, Chief Executive Officer
Michael E. Sneed
Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Paulus A. Stoffels
Vice Chairman- Executive Committee, Chief Scientific Officer
Joaquin Boix Duato
Vice Chairman - Executive Committee
Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Peter M. Fasolo
Chief Human Resource Officer, Executive Vice President
Michael H. Ullmann
Executive Vice President, General Counsel
Ashley McEvoy
Executive Vice President - Worldwide Chairman, Medical Devices
Jorge S. Mesquita
Executive Vice President, Worldwide Chairman - Consumer
Thibaut Mongon
Executive Vice President, Worldwide Chairman, Consumer
Business Overview
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Financial Overview
For the nine months ended 29 September 2019, Johnson & Johnson revenues increased less than 1% to $61.31B. Net income increased 16% to $14.19B., also reflect United States segment decrease of 34% to $20.53B, Europe segment decrease of 33% to $9.34B. Net income benefited from Other (income) expense, net) - Balancing decrease from $200M (expense) to $1.61B (income), Interest expense, net of portion capital decrease of 75% to $185M (expense).
Employees: 135,100 as of Dec 30, 2018
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $81,706M as of Sep 29, 2019
EBITDA (TTM): $30,266M as of Sep 29, 2019
Net annual income (TTM): $17,231M as of Sep 29, 2019
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 2,639,165,527 as of Jul 24, 2019
Index Membership: S&P 500, Dow Industry
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization